12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vpriv velaglucerase alfa regulatory update

FDA issued a complete response letter for an application seeking approval of Shire's Lexington, Mass., manufacturing facility to produce Gaucher's disease therapy Vpriv velaglucerase alfa. According to Shire, the letter included questions related to...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >